Home » ABBOTT LABS SHARES SEEN AS OVERVALUED
ABBOTT LABS SHARES SEEN AS OVERVALUED
UBS Investment Research initiated coverage of Abbott Laboratories with a "reduce" rating and $37 target price.
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May